H.C. Wainwright reiterates Verastem stock rating on durable trial data By Investing.com

H.C. Wainwright reiterated a Buy on Verastem with an $18 price target, while other targets cited ranged from $14 to $19, supported by updated two-year data from the Phase 2 RAMP 201 trial. The data showed a 31.1-month median duration of response overall, 19.6 months PFS in KRAS-mutant patients, and stable safety with about a 12% discontinuation rate. Verastem also reported strong commercial momentum, with revenue up 209% over the last twelve months and gross margin at 85%.

Analysis

The market is still underappreciating how much of VSTM’s rerating is now a quality-of-revenue story, not just a binary drug-readout story. Stable two-year durability plus low discontinuation materially improves the probability that commercial uptake compounds rather than peaks early, which matters because oncology launches tend to re-rate on persistence and prescriber confidence faster than on headline growth alone. The key second-order effect is that a credible, well-tolerated regimen can push competitors in recurrent LGSOC into a slower adoption curve even if they eventually show efficacy, because physicians are reluctant to switch once a durable standard forms.

The biggest near-term catalyst is not additional efficacy data but how quickly the market translates durability into a higher terminal sales multiple over the next 1-2 quarters. If management can show consistent refill behavior, broader payer coverage, and rising dose intensity without safety drift, the current valuation gap can close quickly; if not, the stock can revert to being treated like a one-product microcap biotech with high headline sensitivity. The risk is that investors extrapolate peak penetration too aggressively before real-world persistence data validates the label economics.

Consensus seems focused on whether the drug works; the more important question is whether the approved dose and interruption strategy reduce churn enough to protect lifetime value per patient. That creates optionality if the company can turn a durable therapy into a repeatable commercial engine, but it also makes the stock vulnerable to any signal that adverse-event management or physician education slows initiation. In other words, the setup is favorable, but the rerating depends on execution metrics over the next several months, not just another positive presentation.

Key Decisions for Investors

• Go long VSTM on pullbacks over the next 1-2 weeks; target a 20-30% move over 3-6 months if commercial persistence data confirms durable uptake, but cut if post-launch growth stalls for two consecutive prints.
• Buy VSTM call spreads 3-6 months out rather than outright shares; the asymmetry is driven by re-rating potential, but the single-product execution risk argues for defined downside.
• Pair trade: long VSTM / short a basket of over-earnest oncology monetization names with weaker durability evidence; this isolates the market’s willingness to pay for persistence and label quality rather than just launch optionality.
• Use any spike toward the upper end of sell-side targets to trim 25-35% of the position; upside is meaningful, but valuation will become sensitive to any evidence of slower refill curves or payer friction.